Dose modification or the termination of the drug is indicated in cases of severely decreased kidney function (eGFR < 15 ml/min/1.73m2), suspicion of drug-induced liver injury (aspartate aminotransferase or alanine aminotransferase levels at least five times above the ULN, with a suspected drug-induced liver injury), severe lymphopenia (absolute lymphocyte count < 200 cells/μl), and severe neutropenia (absolute neutrophil count < 500 cells/μl) [3]. This evidence concerns the gene GPT and neutropenia.